{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:11:34Z","timestamp":1790323894150,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00520-026-11157-0","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:59:40Z","timestamp":1788152380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9821-7917","authenticated-orcid":false,"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"11157_CR1","first-page":"603","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA (2019) NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw 17:603\u2013605","journal-title":"J Natl Compr Canc Netw"},{"key":"11157_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.22852","volume":"110","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP et al (2007) Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer 110:738\u2013744","journal-title":"Cancer"},{"key":"11157_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703","journal-title":"N Engl J Med"},{"key":"11157_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y et al (2016) Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77:595\u2013603","journal-title":"Cancer Chemother Pharmacol"},{"key":"11157_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12885-018-5244-2","volume":"19","author":"H Blomstrand","year":"2019","unstructured":"Blomstrand H, Scheibling U, Bratth\u00e4ll C, Green H, Elander NO (2019) Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer 19:40","journal-title":"BMC Cancer"},{"key":"11157_CR6","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1200\/JCO.1996.14.5.1743","volume":"14","author":"YM Chen","year":"1996","unstructured":"Chen YM, Liu JM, Tsai CM, Whang-Peng J, Perng RP (1996) Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer. J Clin Oncol 14:1743\u20131744","journal-title":"J Clin Oncol"},{"key":"11157_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jaad.2008.01.001","volume":"58","author":"N Heidary","year":"2008","unstructured":"Heidary N, Naik H, Burgin S (2008) Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 58:545\u2013570","journal-title":"J Am Acad Dermatol"},{"key":"11157_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/1346-8138.15654","volume":"48","author":"M Tohyama","year":"2021","unstructured":"Tohyama M, Asagi A, Nakasya A, Iuchi S, Hashine K (2021) Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy. J Dermatol 48:215\u2013218","journal-title":"J Dermatol"},{"key":"11157_CR9","first-page":"4279","volume":"15","author":"HB Li","year":"2023","unstructured":"Li HB, Wang WH, Wang ZY (2023) A meta-analysis of the incidence and risk of skin toxicity with nab-paclitaxel and paclitaxel in cancer treatment. Am J Transl Res 15:4279\u20134290","journal-title":"Am J Transl Res"},{"key":"11157_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/annonc\/mdp513","volume":"21","author":"M Kanai","year":"2010","unstructured":"Kanai M, Matsumoto S, Nishimura T, Matsumura Y, Hatano E, Mori A et al (2010) Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy. Ann Oncol 21:189\u2013190","journal-title":"Ann Oncol"},{"key":"11157_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02535-x","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-024-02535-x","journal-title":"Int J Clin Oncol"},{"key":"11157_CR12","unstructured":"Abraxane\u00ae (nanoparticle albumin-bound paclitaxel) [package insert on the internet]. Tokyo; Taiho pharmaceutical Co. https:\/\/www.info.pmda.go.jp\/go\/pack\/4240409D1023_1_17\/?view=frame&style=XML&lang=ja. Accessed 28 Oct 2025"},{"key":"11157_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1365-2125.2010.03774.x","volume":"71","author":"BY Thong","year":"2011","unstructured":"Thong BY, Tan TC (2011) Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71:684\u2013700","journal-title":"Br J Clin Pharmacol"},{"key":"11157_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13223-018-0289-y","volume":"14","author":"R Warrington","year":"2018","unstructured":"Warrington R, Silviu-Dan F, Wong T (2018) Drug allergy. Allergy Asthma Clin Immunol 14:60","journal-title":"Allergy Asthma Clin Immunol"},{"key":"11157_CR15","doi-asserted-by":"crossref","unstructured":"De Moor R, Koroki Y, Wu DB, Yu DY, Tohyama M, Ohyama C (2023) A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan. BMC Urol 23:73","DOI":"10.1186\/s12894-023-01246-1"},{"key":"11157_CR16","unstructured":"GEMZAR\u00ae https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020509s033lbl.pdf. Accessed 28 Oct 2025"},{"key":"11157_CR17","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","volume":"18","author":"AP Venook","year":"2000","unstructured":"Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M et al (2000) Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and leukemia group B 9565. J Clin Oncol 18:2780\u20132787","journal-title":"J Clin Oncol"},{"key":"11157_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cyto.2007.02.015","volume":"37","author":"G Garibotto","year":"2007","unstructured":"Garibotto G, Sofia A, Balbi M, Procopio V, Villaggio B, Tarroni A et al (2007) Kidney and splanchnic handling of interleukin-6 in humans. Cytokine 37:51\u201354","journal-title":"Cytokine"},{"key":"11157_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5527\/wjn.v2.i2.31","volume":"2","author":"HF Tbahriti","year":"2013","unstructured":"Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A et al (2013) Inflammatory status in chronic renal failure: the role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol 2:31\u201337","journal-title":"World J Nephrol"},{"key":"11157_CR20","doi-asserted-by":"crossref","unstructured":"Saito Y, Takekuma Y, Takahashi M, Oshino T, Sugawara M (2024) Evaluation of the impact of systemic dexamethasone dosage on docetaxel-induced hand-foot syndrome in patients with breast cancer. Sci Rep 14:14083","DOI":"10.1038\/s41598-024-64553-z"},{"key":"11157_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00520-015-2846-y","volume":"24","author":"B Dascalu","year":"2016","unstructured":"Dascalu B, Kennecke HF, Lim HJ, Renouf DJ, Ruan JY, Chang JT et al (2016) Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Support Care Cancer 24:799\u2013805","journal-title":"Support Care Cancer"},{"key":"11157_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.5414\/CP203323","volume":"56","author":"Y Iimura","year":"2018","unstructured":"Iimura Y, Shimomura H, Yasu T, Imanaka K, Ogawa R, Ito A et al (2018) NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients. Int J Clin Pharmacol Ther 56:551\u2013554","journal-title":"Int J Clin Pharmacol Ther"},{"key":"11157_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1248\/bpb.b22-00404","volume":"45","author":"R Tanaka","year":"2022","unstructured":"Tanaka R, Ishikawa H, Sato J, Aoyama T, Shikamura Y, Shino M (2022) Prevention of acne-like eruption caused by panitumumab treatment through oral administration of non-steroidal anti-inflammatory drugs. Biol Pharm Bull 45:1531\u20131536","journal-title":"Biol Pharm Bull"},{"key":"11157_CR24","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","volume":"23","author":"RX Zhang","year":"2012","unstructured":"Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23:1348\u20131353","journal-title":"Ann Oncol"},{"key":"11157_CR25","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","volume":"137","author":"RX Zhang","year":"2011","unstructured":"Zhang RX, Wu XJ, Lu SX, Pan ZZ, Wan DS, Chen G (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol 137:953\u2013957","journal-title":"J Cancer Res Clin Oncol"},{"key":"11157_CR26","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/JCO.23.01730","volume":"42","author":"A Santhosh","year":"2024","unstructured":"Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS et al (2024) Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial. J Clin Oncol 42:1821\u20131829","journal-title":"J Clin Oncol"},{"key":"11157_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Leb\u0153uf NR, Roche H, Belum VR, Gladieff L, Deslandres M et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26:427\u2013443","journal-title":"Eur J Dermatol"},{"key":"11157_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gene.2015.01.010","volume":"559","author":"X Ding","year":"2015","unstructured":"Ding X, Chen W, Fan H, Zhu B (2015) Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy. Gene 559:31\u201337","journal-title":"Gene"},{"key":"11157_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32\u201342","journal-title":"J Clin Oncol"},{"key":"11157_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2010.19","volume":"11","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Brasch-Andersen C, Gr\u00e9en H, Mirza M, Pedersen RS, Nielsen F et al (2011) Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenom J 11:113\u2013120","journal-title":"Pharmacogenom J"},{"key":"11157_CR31","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.2147\/OTT.S106574","volume":"9","author":"T Kus","year":"2016","unstructured":"Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. Onco Targets Ther 9:5073\u20135080","journal-title":"Onco Targets Ther"},{"key":"11157_CR32","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1158\/1078-0432.CCR-05-1152","volume":"11","author":"A Henningsson","year":"2005","unstructured":"Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K et al (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11:8097\u20138104","journal-title":"Clin Cancer Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11157-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11157-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11157-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:51:39Z","timestamp":1790322699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11157-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11157"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11157-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards. For this type of study, formal consent was not required by the Ethical Review Board for Life Science and Medical Research of Hokkaido University Hospital.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, formal consent was not required.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"912"}}